Gossamer Bio, Inc. (GOSS) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 8.10
30Y Low2.1·High15.2
ROE
↓
N/A
—
5yr avg: -263.1%
30Y Low-480%·High-72%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GOSS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Gossamer Bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $38M | $708M | $205M | $206M | $184M | $846M | $662M | $856M | — | — | — |
| Enterprise Value | $202M | $873M | $361M | $386M | $297M | $848M | $360M | $760M | — | — | — |
| P/E Ratio → | -0.22 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.78 | 14.62 | 1.78 | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 6.94 | 3.28 | 15.20 | 6.97 | 2.07 | 2.43 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GOSS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 18.00 | 3.15 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
GOSS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Gossamer Bio, Inc. earns an operating margin of -336.8%. Operating margins have compressed from -52.2% to -336.8% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.9% | 97.9% | 100.0% | — | — | — | — | — | — | — | — |
| Operating Margin | -336.8% | -336.8% | -52.2% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -351.5% | -351.5% | -49.3% | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -122.5% | -480.5% | -343.5% | -105.8% | -72.3% | -155.6% | — | — | — |
| ROA | -69.9% | -69.9% | -18.0% | -61.5% | -74.5% | -53.0% | -50.4% | -54.3% | -122.5% | -2681.6% | -138.3% |
| ROIC | -107.5% | -107.5% | -20.9% | -74.7% | -131.6% | -228.9% | -114.7% | -880.2% | — | — | — |
| ROCE | -86.1% | -86.1% | -22.6% | -76.0% | -83.0% | -53.7% | -47.3% | -61.2% | -136.6% | — | — |
GOSS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $164M ($202M total debt minus $38M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 6.88 | 3.38 | 18.69 | 1.53 | 0.57 | 0.11 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 5.32 | 2.87 | 9.42 | 0.02 | -0.94 | -0.27 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -1.00 |
| Interest Coverage | -14.86 | -14.86 | -3.83 | -12.31 | -15.53 | -11.04 | -18.21 | — | -12246.42 | -56.38 | — |
GOSS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Gossamer Bio, Inc.'s current ratio of 2.64x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.94x to 2.64x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.64 | 2.64 | 6.88 | 5.94 | 5.32 | 8.32 | 13.51 | 11.09 | 11.37 | 0.35 | 0.42 |
| Quick Ratio | 2.64 | 2.64 | 6.88 | 5.94 | 5.32 | 8.32 | 13.51 | 11.09 | 11.37 | 0.35 | 0.42 |
| Cash Ratio | 2.16 | 2.16 | 6.54 | 5.74 | 5.19 | 8.16 | 13.26 | 10.88 | 11.21 | 0.25 | 0.42 |
| Asset Turnover | — | 0.28 | 0.36 | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 94.33 | 16.99 | — | — | — | — | — | — | — | — |
GOSS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Gossamer Bio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $229M | $226M | $226M | $85M | $75M | $69M | $55M | $60M | $25M | $9M |
Peer Comparison
Compare GOSS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GOSSYou | $38M | -0.2 | — | — | 97.9% | -336.8% | — | -107.5% | — |
 ARWR | $10B | -6108.2 | 87.0 | 66.9 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 MNKD | $1B | 183.0 | 29.9 | 82.6 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 AVXL | $232M | -4.6 | — | — | — | — | -43.1% | — | — |
 KALA | $58M | -0.8 | — | — | — | — | -279.2% | — | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 UTHR | $23B | 19.6 | 13.5 | 22.3 | 87.9% | 47.7% | 19.7% | 21.5% | — |
 LGND | $5B | 41.7 | 66.7 | 104.7 | 97.5% | 17.6% | 13.5% | 3.4% | 5.6 |
 IDYA | $3B | -22.6 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 PCVX | $7B | -8.4 | — | — | — | — | -25.6% | -24.2% | — |
 LUNG | $58M | -1.0 | — | — | 74.2% | -59.3% | -77.2% | -72.0% | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
What if you invested $1,000 in GOSS 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in GOSS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs GOSS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationGOSS vs ARWR — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Arrowhead Pharmaceuticals, Inc..
Compare NowGOSS — Frequently Asked Questions
Quick answers to the most common questions about buying GOSS stock.
What is Gossamer Bio, Inc.'s P/E ratio?
Gossamer Bio, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Is GOSS stock overvalued?
Based on historical data, Gossamer Bio, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Gossamer Bio, Inc.'s profit margins?
Gossamer Bio, Inc. has 97.9% gross margin and -336.8% operating margin.